Damora Therapeutics (DMRA) EPS (Weighted Average and Diluted) (2021 - 2026)
Damora Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.62 for Q1 2026, up 67.71% year-on-year from -$0.37 in Q1 2025, and down 105.71% on a QoQ basis from $10.86 in Q4 2025.
Damora Therapeutics (DMRA) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.62 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 67.71% year-over-year to -$0.62; the trailing twelve-month figure through Mar 2026 stood at $5.28 (up 134.15% YoY), and the FY2025 full-year result was $3.98, up 121.48% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.62, down from $10.86 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $10.86 in Q4 2025 and bottomed at -$7.5 in Q3 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.92 (2025), against an average of -$1.88.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) slumped 1288.89%; it then jumped 307.65% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.55 in 2022, then plunged by 970.91% to -$5.89 in 2023, then advanced by 11.21% to -$5.23 in 2024, then jumped by 307.65% to $10.86 in 2025, then sank by 105.71% to -$0.62 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.62 (Q1 2026), $10.86 (Q4 2025), and -$2.36 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -0.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.62 |
| Dec 31, 2025 | 10.86 |
| Sep 30, 2025 | -2.36 |
| Jun 30, 2025 | -2.60 |
| Mar 31, 2025 | -1.92 |
| Dec 31, 2024 | -5.23 |
| Sep 30, 2024 | -3.39 |
| Jun 30, 2024 | -4.92 |
| Mar 31, 2024 | -5.05 |
| Dec 31, 2023 | -5.89 |
| Sep 30, 2023 | -7.50 |
| Jun 30, 2023 | -0.41 |
| Mar 31, 2023 | -0.51 |
| Dec 31, 2022 | -0.55 |
| Sep 30, 2022 | -0.54 |
| Jun 30, 2022 | -0.67 |
| Mar 31, 2022 | -0.67 |
| Dec 31, 2021 | -0.53 |
| Sep 30, 2021 | -0.50 |